Frontlight ResearchEarly access
CompletedPhase 1
Psilocybin for Treatment of Obsessive Compulsive Disorder
Key facts
- Who runs it
- University of Arizona
- Where
- Tucson, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 15 people enrolled
- Started
- 2 Jan 2019
- Ended
- 30 Dec 2023
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Psilocybin 100 mcg/kg
- Psilocybin 300 mcg/kg
- Lorazepam 1 mg
- Record updated
- 30 August 2024
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Have moderate to severe OCD (DSM-5) after diagnostic interview using the Structured Clinical Interview for DSM-5 Research Version (SCID-R)
- Failed at least one adequate attempted routine care treatment
- Considered safe for independent living
Who cannot take part
- Concurrent psychosis, active substance use disorder, or a personal history of psychosis
- Subjects may not be using antidepressant medication for OCD for at least two weeks before receiving study drug, and they cannot require any sedative, narcotic, or neuroleptic medications on a regular basis. Any of these medications they have taken should have been stopped long enough in the past to allow for their elimination and safe withdrawal prior to starting administration of the study drug. The specific time required will be dependent on the medication the patient was previously receiving
- Medical illness based on physical examination and routine blood testing that may complicate cardiovascular safety or drug metabolism or excretion, such as uncontrolled hypertension, severe cardiac disease, or kidney or liver failure
- Unstable Chronic Obstructive Pulmonary Disease (COPD) or severe sleep apnea
- Psychiatric comorbidity that may represent an acute risk to their own or others' safety
- Allergy to lorazepam
- Women who are pregnant, breastfeeding, or unwilling/unable to practice medically acceptable birth control during the study
Where in United States
- University of ArizonaTucson, United States
About the trial
What the trial wants to find out
This study will evaluate whether psilocybin, a hallucinogenic drug, improves symptoms of obsessive compulsive disorder (OCD), whether it is safely tolerated as treatment of OCD, and will investigate the mechanisms by which it works.
The 3 groups in the trial
- High-dose PsilocybinTreatment being tested
Psilocybin 300 mcg/kg once per week, every week, for 8 weeks
Treatment: Psilocybin 300 mcg/kg
- High- or Low-dose PsilocybinTreatment being tested
Psilocybin 100 mcg/kg or psilocybin 300 mcg/kg once per week, every week, for 8 weeks
Treatment: Psilocybin 100 mcg/kg and Psilocybin 300 mcg/kg
- High-dose Psilocybin or LorazepamPlacebo, for comparison
Psilocybin 300 mcg/kg or Lorazepam 1 mg once per week, every week, for 8 weeks
Treatment: Psilocybin 300 mcg/kg and Lorazepam 1 mg
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder.Journal of psychopharmacology (Oxford, England), 2026
- Record updated
- 30 August 2024